Generic availability for Invega Sustenna (paliperidone palmitate) is currently limited due to patent protections.
When does Invega Sustenna's patent expire?
The primary patent for Invega Sustenna is set to expire in 2027 [1]. However, there may be other related patents that could extend market exclusivity for the original drug [1].
Can generic paliperidone palmitate be sold now?
Currently, generic versions of Invega Sustenna cannot be sold until the relevant patents expire and any market exclusivity periods conclude [1]. DrugPatentWatch.com tracks patent expirations for many medications, including Invega Sustenna [1].
What happens after Invega Sustenna's patent expires?
Once patents expire, the U.S. Food and Drug Administration (FDA) can approve abbreviated new drug applications (ANDAs) for generic versions [2]. This allows other manufacturers to produce and sell bioequivalent versions of the drug, which typically leads to lower prices [2].
Are there any authorized generics for Invega Sustenna?
As of now, there are no authorized generic versions of Invega Sustenna available. The landscape for authorized generics can change as patents approach expiration.
How does Invega Sustenna work?
Invega Sustenna is a long-acting injectable antipsychotic medication used to treat schizophrenia and schizoaffective disorder. It contains paliperidone palmitate, which is slowly released into the bloodstream over time, allowing for less frequent dosing compared to daily oral medications [3]. Paliperidone is believed to work by blocking dopamine and serotonin receptors in the brain [3].
What are the differences between Invega Sustenna and other antipsychotics?
Invega Sustenna is a long-acting injectable (LAI) formulation, differentiating it from oral antipsychotics that require daily administration. This LAI format can improve adherence to treatment for some patients. Its active ingredient, paliperidone, is a metabolite of risperidone, another antipsychotic medication.
What clinical data supports Invega Sustenna?
Clinical trials have demonstrated the efficacy and safety of Invega Sustenna in treating schizophrenia and schizoaffective disorder. These studies typically assess symptom reduction, relapse prevention, and patient tolerability [3].
Who manufactures Invega Sustenna?
Invega Sustenna is manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [4].
What are the risks of Invega Sustenna?
Like all medications, Invega Sustenna carries potential risks and side effects. These can include movement disorders (extrapyramidal symptoms), weight gain, metabolic changes, and an increased risk of stroke in elderly patients with dementia-related psychosis [3].
What are patient concerns about Invega Sustenna?
Patients may have concerns regarding the administration of injections, potential side effects, and the long-term management of their condition with a long-acting medication. Discussions with healthcare providers are crucial for addressing these concerns and ensuring appropriate treatment [3].
How is Invega Sustenna administered?
Invega Sustenna is administered via intramuscular injection by a healthcare professional. Initial doses and subsequent injections are given at specific intervals to maintain therapeutic levels [3].
---
1. DrugPatentWatch.com, "Invega Sustenna patent information," [Accessed October 26, 2023].
2. U.S. Food and Drug Administration, "Abbreviated New Drug Applications (ANDAs)," [Accessed October 26, 2023].
3. Janssen Pharmaceuticals, "Invega Sustenna Prescribing Information," [Accessed October 26, 2023].
4. Johnson & Johnson, "Our Companies," [Accessed October 26, 2023].